Aarti Pharmalabs Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹610 Cr +45.9% YoYSee revenue, profit and what management said. You are viewing Q3 FY26.
AP

Aarti Pharmalabs Ltd

Q3 FY26Pharmaceuticals & Biotechnology

Aarti Pharmalabs Q3 FY26 earnings call: Revenue & Margins

Q3 FY26 earnings call: what management said on revenue, margins and capex.

Revenue
₹432Cr
−19.7% YoY
+3.3% QoQ
Net profit
₹48Cr
−35.1% YoY
+71.4% QoQ
Margin
24%
0 pp YoY
+6 pp QoQ
Price₹817
Market cap₹6.2K Cr
P/E35.0

The short version

CDMO business expected to see good growth; FY '27 guidance to be prepared post budgeting in March 2026. The company anticipates good growth in the CDMO business for FY '27, with budgeting and detailed guidance to be finalized by March.

From Aarti Pharmalabs Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • CDMO business expected to see good growth; FY '27 guidance to be prepared post budgeting in March 2026.
  • Potential for substantial growth due to small base and possible 1-2 good commercial opportunities.
  • CDMO sales target: INR 1,000 crores; aiming for similar growth in FY '27 as FY '26.
  • Increasing wallet share with innovator partners; around 7-8 projects anchor 80% of CDMO sales.
  • New commercial molecules (from ~28 to 40) progressing to scale up revenues.
  • Xanthine segment planning 25-30%+ volume growth next year; with 5-10% realization improvement due to China-related dynamics.
  • API segment currently slow with some degrowth; expected to recover with new product launches and capacity expansion (including Atali plant).

2 more points from Aarti Pharmalabs Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Aarti Pharmalabs Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Aarti Pharmalabs plans capital expenditure (capex) for FY27-FY28 focused on expansions:
  • Atali site: At least one new manufacturing block is planned for FY27 with capex approval forthcoming; described as not a large capex.
  • Xanthine site: Approved capex is around INR150 crores for both sites combined, with an ongoing capacity increase targeting 9,000 tonnes per annum by end of Q4.
  • Capex at Atali includes INR450 crores total:
  • INR300 crores commercialized.
  • INR150 crores balance remaining.

2 more points from Aarti Pharmalabs Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Aarti Pharmalabs Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • The company has single purchase orders (POs) in the range of single-digit millions of dollars, indicating sizeable orders.
  • At the end of FY '25, the company had 21 CDMO customers; the number is expected to increase in calendar year 2026.
  • A good number of new CDMO inquiries have been generated starting this year, with hopes to win multiple RFPs.
  • The CDMO business pipeline includes 5-7 significant projects anchoring 80% of sales, with a dynamic list of about 60 projects being tracked.
  • There is a mix of customers including innovators, CDMO partners, smaller biotechs, and traders.
  • Some projects have wallet shares of 60-70%, indicating deep involvement in product manufacturing.

2 more points from Aarti Pharmalabs Ltd's call on order book

Create a free account to keep reading this call

Aarti Pharmalabs Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Aarti Pharmalabs Ltd Q3 FY26 results — key figures

Aarti Pharmalabs Ltd Q3 FY26 reported results vs Q3 FY25, ₹ crore
₹ CrQ3 FY26Q3 FY25YoYQ2 FY26QoQ
Revenue432538-19.7%418+3.3%
Operating profit (EBITDA)102129-20.9%74+37.8%
Operating margin24%24%0 pp18%+6 pp
Profit before tax63101-37.6%39+61.5%
Net profit (PAT)4874-35.1%28+71.4%
EPS (₹)5.298.16-35.2%3.08+71.8%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹610 Cr, net profit ₹71 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • Natural Capsules (Q3 FY26)

    Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks

  • Wanbury (Q3 FY26)

    Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against

  • Gujarat Themis Biosyn (Q3 FY26)

    43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against

  • Balaxi Pharma (Q3 FY26)

    Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Aarti Pharmalabs Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Aarti Pharmalabs Ltd Q3 FY26 results?

CDMO business expected to see good growth; FY '27 guidance to be prepared post budgeting in March 2026. The company anticipates good growth in the CDMO business for FY '27, with budgeting and detailed guidance to be finalized by March.

What is Aarti Pharmalabs Ltd share price analysis?

Aarti Pharmalabs Ltd currently shows a neutral. The stock trades at a P/E of 35.0 with a market cap of ₹6,193 Cr. Investors should review the full earnings analysis for detailed insights.

Is Aarti Pharmalabs Ltd planning capital expenditure?

Aarti Pharmalabs plans capital expenditure (capex) for FY27-FY28 focused on expansions: - Atali site: At least one new manufacturing block is planned for FY27 with capex approval forthcoming; described as not a large capex.

Keep Aarti Pharmalabs Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.